强直性脊柱炎患者使用他汀类药物与生存获益的关联:一项普通人群队列研究
该研究基于英国普通人群数据库,采用时间分层倾向评分匹配的起始用药者队列设计,比较强直性脊柱炎(AS)患者中他汀起始者与非起始者的死亡风险。匹配后他汀起始者死亡率显著低于非起始者(HR=0.63,95%CI 0.46-0.85),提示他汀使用与AS患者死亡风险降低相关。
要点
- 匹配后他汀起始者死亡风险显著降低(HR=0.63,95%CI 0.46-0.85)。
- 绝对死亡率差为每1000人年减少7.3例死亡(95%CI 2.1-12.5)。
- 未匹配分析中他汀起始者死亡风险反而更高(HR=1.43),提示强指征混杂。
核心结论
- 在普通人群背景下,强直性脊柱炎患者起始他汀治疗与死亡风险显著降低相关。
研究设计与样本
- 基于英国普通人群数据库(2000年1月1日至2014年12月31日)的起始用药者队列研究,采用时间分层倾向评分匹配。
- 倾向评分模型纳入变量包括疾病病程、体重指数、生活方式因素、合并症和用药情况。
主要发现
- 未匹配队列中,他汀起始者(n=1430)死亡风险比非起始者(n=1430)高43%(HR=1.43;95%CI 1.12-1.84)。
- 倾向评分匹配后,他汀起始者(n=1108)平均随访5.3年发生96例死亡,匹配非起始者(n=1108)平均随访5.1年发生134例死亡。
- 匹配后死亡率分别为每1000人年16.5例和23.8例,HR=0.63(95%CI 0.46-0.85),绝对死亡率差为每1000人年7.3例(95%CI 2.1-12.5)。
临床怎么用
- 在强直性脊柱炎患者中,他汀起始治疗可能与死亡风险降低相关,支持对该人群心血管风险管理中他汀使用的进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recent studies have shown an increase in both cardiovascular and all-cause mortality in ankylosing spondylitis (AS). We examined the potential survival benefit of statin use in AS within a general population context. METHODS: We performed an incident user cohort study with time-stratified propensity score matching using a UK general population database between 1 January 2000 and 31 December 2014. To account for potential confounders, we compared propensity score-matched cohorts of statin initiators and non-initiators using 1-year cohort accrual blocks. The variables used to create the propensity score model included disease duration, body mass index, lifestyle factors, comorbidities and medication use. RESULTS: Using unmatched AS cohorts, statin initiators (n=1430) showed a 43% higher risk of mortality than non-initiators (n=1430) (HR=1.43; 95% CI 1.12 to 1.84). After propensity score matching, patients with AS who initiated statins (n=1108) had 96 deaths, and matched non-initiators (n=1108) had 134 deaths over a mean follow-up of 5.3 and 5.1 years, respectively. This corresponded to mortality rates of 16.5 and 23.8 per 1000 person-years (PY), respectively, resulting in an HR of 0.63 (95% CI 0.46 to 0.85) and an absolute mortality rate difference of 7.3 deaths per 1000 PY (95% CI 2.1 to 12.5). CONCLUSION: This general population-based cohort study suggests that statin initiation is associated with a substantially lower risk of mortality among patients with AS. The magnitude of the inverse association appears to be larger than that observed in randomised trials of the general population and in population-based cohort studies of patients with rheumatoid arthritis.
引用
- Oza A, Lu N, Schoenfeld SR, et al. Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis. 2017. PMID: 28698231. doi:10.1136/annrheumdis-2017-211253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。